Suprathreshold dosing of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A case series.

Abstract

Supratherapeutic dosing of selective serotonin reuptake inhibitors (SSRIs) in obsessive-compulsive disorder (OCD) is an area of clinical interest, particularly for treatment-resistant cases. Standard SSRI doses often provide insufficient symptom relief, prompting clinicians to explore higher-than-recommended doses. Evidence suggests that supratherapeutic dosing can enhance serotonergic activity, potentially improving treatment response. However, the risk-benefit profile must be carefully considered due to side effects. While some studies support its efficacy, individual response varies, necessitating close monitoring. Further research is needed to establish optimal dosing strategies and long-term safety in OCD patients requiring intensified SSRI therapy.